Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 microg/24h and 16 microg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years.

Trial Profile

Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 microg/24h and 16 microg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms LCS Pearl Index Study
  • Sponsors Bayer; Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2016 According to a Bayer media release, based on the results of this trial, the US FDA granted marketing approval low dose levonorgestrel-releasing intrauterine system (LNG-IUS, Kyleena) for protection against pregnancy for up to 5 years.
    • 20 Nov 2015 According to media release of Bayer HealthCare Pharmaceuticals, New Drug Application (NDA) is submitted to the U.S. Food and Drug Administration for approval for LCS-16 for pregnancy protection for up to five years.
    • 14 Nov 2013 Results published in Obstetrics and Gynecology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top